Last reviewed · How we verify
PGN-EDODM1
At a glance
| Generic name | PGN-EDODM1 |
|---|---|
| Sponsor | PepGen Inc |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (PHASE2)
- Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myotonic Dystrophy Type 1 (PHASE1)
- An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PGN-EDODM1 CI brief — competitive landscape report
- PGN-EDODM1 updates RSS · CI watch RSS
- PepGen Inc portfolio CI